Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabien Subtil

Showing results (121-130 of 165) with videos related to

Pageof 17
Sort By:
Biomedicines|June 28, 2023
Performance of 11 Host Biomarkers Alone or in Combination in the Diagnosis of Late-Onset Sepsis in Hospitalized Neonates: The Prospective EMERAUDE StudySylvie Pons, Sophie Trouillet-Assant, Fabien Subtil, et al.
The Journal of Antimicrobial Chemotherapy|April 24, 2024
Correlation between antifungal clinical practices and a new clinical decision support system ANTIFON-CLIC® for the treatment of invasive candidiasis: a retrospective multicentre studyAnne-Lise Bienvenu, Martin Cour, Patricia Pavese, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyJean-Marc Phelip, Véronique Vendrely, Florian Rostain, et al.
BMJ Open|September 5, 2024
Evaluating the impact of a standardised intervention for announcing decisions of withholding and withdrawing life-sustaining treatments on the stress of relatives in emergency departments (DISCUSS): protocol for a stepped-wedge randomised controlled trialAnne Termoz, Fabien Subtil, Pauline Drouin, et al.
Biomolecules|August 26, 2023
Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular ProfilingEmmanuel Grolleau, Julie Candiracci, Gaelle Lescuyer, et al.
Open Forum Infectious Diseases|March 5, 2020
A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast MilkAlpha Kabinet Keita, Nicole Vidal, Abdoulaye Toure, et al.
Pediatric Nephrology (Berlin, Germany)|September 9, 2020
Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobsSegolene Gaillard, Laurent Roche, Sandrine Lemoine, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trialOlivier Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
The Lancet. Oncology|June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialJulien Taieb, Josep Tabernero, Enrico Mini, et al.
Pageof 17

Showing results (121-130 of 165) with videos related to

Sort By:
Pageof 17
Biomedicines|June 28, 2023
Performance of 11 Host Biomarkers Alone or in Combination in the Diagnosis of Late-Onset Sepsis in Hospitalized Neonates: The Prospective EMERAUDE StudySylvie Pons, Sophie Trouillet-Assant, Fabien Subtil, et al.
The Journal of Antimicrobial Chemotherapy|April 24, 2024
Correlation between antifungal clinical practices and a new clinical decision support system ANTIFON-CLIC® for the treatment of invasive candidiasis: a retrospective multicentre studyAnne-Lise Bienvenu, Martin Cour, Patricia Pavese, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyJean-Marc Phelip, Véronique Vendrely, Florian Rostain, et al.
BMJ Open|September 5, 2024
Evaluating the impact of a standardised intervention for announcing decisions of withholding and withdrawing life-sustaining treatments on the stress of relatives in emergency departments (DISCUSS): protocol for a stepped-wedge randomised controlled trialAnne Termoz, Fabien Subtil, Pauline Drouin, et al.
Biomolecules|August 26, 2023
Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular ProfilingEmmanuel Grolleau, Julie Candiracci, Gaelle Lescuyer, et al.
Open Forum Infectious Diseases|March 5, 2020
A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast MilkAlpha Kabinet Keita, Nicole Vidal, Abdoulaye Toure, et al.
Pediatric Nephrology (Berlin, Germany)|September 9, 2020
Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobsSegolene Gaillard, Laurent Roche, Sandrine Lemoine, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trialOlivier Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
The Lancet. Oncology|June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialJulien Taieb, Josep Tabernero, Enrico Mini, et al.
Pageof 17